APA (7th ed.) Citation

Reck, M., & Thomas, M. (2016). Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). Oncology research and treatment, 39(9), . https://doi.org/10.1159/000448085

Chicago Style (17th ed.) Citation

Reck, Martin, and Michael Thomas. "Necitumumab Plus Gemcitabine and Cisplatin as First-line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-small-cell Lung Cancer: German Subgroup Data from an Open-label, Randomized Controlled Phase 3 Study (SQUIRE)." Oncology Research and Treatment 39, no. 9 (2016). https://doi.org/10.1159/000448085.

MLA (9th ed.) Citation

Reck, Martin, and Michael Thomas. "Necitumumab Plus Gemcitabine and Cisplatin as First-line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-small-cell Lung Cancer: German Subgroup Data from an Open-label, Randomized Controlled Phase 3 Study (SQUIRE)." Oncology Research and Treatment, vol. 39, no. 9, 2016, https://doi.org/10.1159/000448085.